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Schizophrenia is a debilitating psychotic disorder characterized by positive symptoms
such as delusions, hallucinations, and disorganized thoughts, and negative symptoms like
lack of effect or motivation. Bipolar 1 disorder (B1D) is a psychiatric illness characterized
by recurrent manic episodes in alternation with depressive episodes and interspersed
periods of euthymia, ultimately resulting in psychological distress and impairment of
daily functioning. Effective treatments are needed for both schizophrenia and B1D to
reach the treatment goals of reducing the debilitating symptomology, improving social
functioning and quality of life, and increasing the chances of recovery and more favorable
long-term outcomes. To date, olanzapine is one of the most efficacious atypical
antipsychotics (AAPs) for the treatment of both schizophrenia and B1D and is associated
with fewer extrapyramidal effects compared to other treatments. However, compared to
other AAPs, olanzapine is associated with a greater chance of metabolic syndrome,
limiting its clinical use and affecting treatment compliance. Samidorphan mitigates the
weight gain side effects of olanzapine by antagonizing μ-, κ-, and δ-opioid receptors. The
use of combination drugs to treat psychiatric conditions is an emerging field with the goal
of increasing therapeutic efficacy and decreasing undesirable side effects. Clinical trials
have demonstrated combination on olanzapine and samidorphan (OLZ/SAM) treatment
resulted in significantly less weight gain than olanzapine monotherapy. Clinical trial
patients reported improvements in symptoms of psychosis, reduced weight gain, and
overall satisfaction with their treatment. OLZ/SAM has been as shown to be a safe and
effective pharmaceutical option for the clinical management of schizophrenia and B1D.

INTRODUCTION
Schizophrenia, derived from the Greek ‘schizo’ and ‘phren’
meaning ‘splitting mind,’ is a debilitating psychotic disorder characterized by positive symptoms such as delusions,
hallucinations, and disorganized thoughts, and negative
symptoms like lack of effect or motivation.1,2 The disease
has a multifactorial etiology with many associated risk factors, including maternal malnutrition, influenza during
gestation, cannabis use, urbanization, and birthing complications.1,3 The diagnosis of schizophrenia is clinical and re-
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quires the exclusion of any other potential causes of psychosis.
Although schizophrenia has a low prevalence affecting
about 1% of the world’s population, psychotic disorder carries a significant burden of disease.3,4 Schizophrenia is one
of the leading causes of disability and death worldwide.3
Life expectancy is reduced by 20% in those with schizophrenia with up to 40% of schizophrenia-related deaths attributed to suicide.1 The economic burden of the disease of
schizophrenia is substantial. Annual costs are estimated to
range from $94 million to $106 billion globally and more
than $60 billion in the United States.4 The economic disease
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burden is measured in direct medical, direct nonmedical,
and indirect costs, with indirect costs contributing most
to the overall burden. Examples of indirect costs include
unemployment, income assistance, morbidity, law enforcement, and more.4
Bipolar 1 disorder (B1D) is a psychiatric illness characterized by recurrent manic episodes in alternation with depressive episodes and interspersed periods of euthymia, ultimately resulting in psychological distress and impairment
of daily functioning.5 While the basis of B1D has been identified as largely biological, the disease course and symptomology can vary greatly depending on psychological, and
environmental social factors.6,7 Identified risk factors for
B1D include pre-existing anxiety and disruptive behavioral
disorders, maternal influenza infection, preterm birth, head
injury, and physical or sexual abuse.8 The lifetime and
12-month prevalence rates for B1D are estimated to be 2.4%
and 1.5%, respectively.5
B1D has a high comorbidity association with both
chronic medical conditions and other psychiatric conditions, resulting in an increased burden of disease and worsened prognosis. Common comorbidities include anxiety,
substance abuse, personality disorders, metabolic syndrome, migraine, and obesity.5 Consequently, those with
B1D are at much higher risk for premature death with an
estimated loss of 10-20 potential years of life, with suicide
or cardiovascular disease being the most common causes of
death.9
The current estimated economic burden of bipolar disease in the United States is more than $195 billion annually,
with 72-80% of costs being indirect rather than direct medical costs. Major drivers of the high economic burden associated with B1D include unemployment, lost work productivity for patients and caregivers, frequent psychiatric
interventions, and high rate of comorbid conditions requiring clinical management.10
Effective treatments are needed for both schizophrenia
and bipolar disorder to reach the treatment goals of reducing the debilitating symptomology, improving social functioning and quality of life, and increasing the chances of
recovery.9,11 Combination of olanzapine and samidorphan
(OLZ/SAM) has been recently Food and Drug Administration (FDA) approved for the treatment of both schizophrenia and bipolar I disorder after showing statistical improvement in clinical trials.12

METHODS
The present investigation is a narrative review. In 2021,
a comprehensive search was performed using the PubMed
database for studies related to the topic of OLZ/SAM for
treatment of schizophrenia and B1D. We searched the following keywords: schizophrenia, bipolar disorder, Lybalvi,
olanzapine, samidorphan. Priority for inclusion was given
to recent manuscripts (within the last three years), but relevant papers older than three years were also included. An
attempt to search for, use, and cite primary manuscripts
whenever possible was also made. This article, therefore, is
based on previously conducted studies and does not contain
any new studies with human participants or animals performed by any of the authors.

EPIDEMIOLOGY, PRESENTATION, AND
PATHOPHYSIOLOGY OF SCHIZOPHRENIA AND
BIPOLAR 1 DISORDER
PREVALENCE OF SCHIZOPHRENIA

Recent studies estimate the global number of individuals
with schizophrenia to be 21 million people worldwide or
roughly 1% of the population.13,14 Prevalence studies have
observed no sex differences amongst those affected by
schizophrenia.14,15 Higher incidence rates are reported in
African-Caribbean migrants and their descendants.1,16
ETIOLOGY AND RISK FACTORS OF SCHIZOPHRENIA

Schizophrenia is a heterogeneous psychiatric illness with a
multifactorial cause. Factors contributing to the etiology of
schizophrenia include neurobiological, genetic, psychosocial, and environmental. The neurobiological component of
schizophrenia is largely related to abnormalities in neurotransmitter signaling.1 Family and twin studies have illustrated a genetic component of schizophrenia, as well.
Monozygotic twin studies have shown varying heritability
rates ranging from 40%-80% with overall heritability of
schizophrenia estimated to be around 80%.13,17–19 Circumstances in which both parents are affected by schizophrenia
carry an estimated 40% risk of the offspring developing
schizophrenia.1
Certain psychosocial or environmental risk factors have
a high association with the development of schizophrenia,
which includes but are not limited to low birth weight,
emergency cesarean section or other birthing complications, maternal infection, residing in urban areas, childhood trauma, early stress, gestational diabetes, preeclampsia, advanced paternal age, substance abuse, and comorbid
psychiatric illnesses.1,17,20,21 Recent longitudinal studies
have shown a dose-effect relationship between cannabis usage and a 40% increase in the risk of development of schizophrenia.1
PRESENTATION OF SCHIZOPHRENIA

Schizophrenia commonly presents in early adulthood
(early-onset schizophrenia) but can also present with older
age (late-onset schizophrenia).20 Symptoms are separated
into categories of positive and negative symptoms. Positive
symptoms include the symptoms of psychosis, delusions,
and hallucinations, as well as disorganized thought and behavior. Negative symptoms include alogia, avolition, social
withdrawal, deficits in executive function, and diminished
or loss of emotional expression.13 Most people suffering
from schizophrenia have significant psychosocial dysfunction resulting in impairment of daily functioning in areas
of work, interpersonal relations, or self-care.13,15 In addition, those with schizophrenia are more likely to be homeless, unemployed, or live-in poverty. Finally, schizophrenia
is associated with a significantly reduced life expectancy
with most deaths attributable to sequelae from comorbid
illnesses.15,22
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PATHOPHYSIOLOGY OF SCHIZOPHRENIA

The idea of a genetic role in the development of schizophrenia is well-established. Genome-wide association studies
have identified numerous genes implicated in the development of schizophrenia, including but not limited to neuregulin (NGR1), dysbindin (DTNBP1), and catecholamine Omethyl transferase (COMT) Val158Met polymorphism.1,17
NGR1 is involved in glutamate signaling and brain development, DTNBP1 aids in the release of glutamate, and COMT
regulate dopamine function.1 While the aforementioned
genes have been more widely studied thus far in relation to
schizophrenia, genome-wide association studies have identified a total of 108 schizophrenia-associated loci.21,23 It
has been postulated that epigenetic changes in expression
levels of the COMT polymorphism and other genetic polymorphisms may have a relationship between traumatic life
events and the development of schizophrenia.17,21,24,25
Further studies are currently exploring gene-environment
interactions and their effect, if any, on schizophrenia. Additionally, a 22q11.2 chromosomal deletion has been discovered with a 30-40% associative risk of schizophrenia development.13
The neurobiological basis of schizophrenia is largely
based on defective neurotransmitter signaling, specifical
hyperactivity in dopaminergic, serotoninergic, and alphaadrenergic circuits, or hypoactivity in glutaminergic and
GABAergic circuits.1 Aberrant neural circuitry as a result of
defective synaptic pruning and the associated increase in
gray matter loss is associated with the cognitive deficits in
schizophrenia from the resultant excitatory-inhibitory imbalance.13,26–28 Irregular dopamine signaling in mesostriatal dopamine networks is highly associated with schizophrenia.13 Positive symptoms are likely a result of excessive
dopamine activity in the mesolimbic pathway, while negative symptoms are likely a result of reduced dopamine activity in the nigrostriatal pathway.1,29 Finally, it has been discovered that hippocampal neurons in the CA1 region have
shown increased glutamatergic activity in concordance with
the developmental progression of psychotic symptoms from
prodromal to syndromal as observed in longitudinal studies. The glutamate-driven hypermetabolism in specific hippocampal regions ultimately leads to reduced hippocampal
volume in the brains of schizophrenia patients.30
PREVALENCE OF BIPOLAR

1 DISORDER

B1D is an unpredictable fluctuating mood disorder that
generally presents early in life with a mean onset age of 20
and of similar prevalence in men and women.31 B1D affects
an estimated 2.4% of the world’s population or about 45
million people.5,32 Current estimates indicate that bipolar
disease is the 17th leading cause of global burden of disease
behind schizophrenia and other psychiatric illnesses.31
ETIOLOGY AND RISK FACTORS OF BIPOLAR

1 DISORDER

It is well-established that bipolar disorder has a heterogeneous etiology. Factors contributing to the development of
B1D include family history and genetics, along with environmental, social, neuropsychological, and biological vari-

ables. Results from twin heritability studies report the heritability of B1D at around 70%9; however, the development
of B1D also appears to be largely dependent upon interactions between genetics and environmental risk factors and
not heritability alone.8
While there are many risk factors associated with bipolar
disorder, such as pre-existing anxiety disorders, pregnancy,
and birth complications, and substance abuse, very few risk
factors show strong enough specificity to unequivocally link
the risk to the development of the bipolar disorder.8 An exception is the significant relationship that exists between
experiencing childhood trauma and developing B1D with
earlier onset and greater severity of the disease.17,33 Although the exact mechanism has not yet been ascertained,
there are numerous working theories investigating the
physiologic link between exposure to stressors during neurodevelopmental stages and the development of B1D, which
will be explored further in the pathophysiology section.33
PRESENTATION OF BIPOLAR

1 DISORDER

Bipolar disorder has an age of onset around adolescence
or early adulthood, generally after preceding subclinical
symptoms have appeared. B1D presents with alternating
manic and depressive episodes with euthymic episodes in
between.33 Manic episodes generally last over one week and
present with characteristics such as distractibility, impulsivity, elevated mood, overconfidence, grandiosity, talkativeness, and decreased need for sleep. Depressive episodes
include experiences of anhedonia, low mood, decreased energy, and feelings of hopelessness or worthlessness.6 The
culmination of symptoms presenting with B1D results in
overall reduced quality of life, especially during the presence of depressive symptoms.31,34 Patients with B1D have
a significantly higher unemployment rate and divorce/separation rate as compared to the general population along
with cognitive impairment affecting activities of daily living, further contributing to reduced quality of life.31,34–36
The poor quality of life seen in patients with B1D ultimately
results in reduced educational attainment and the ability
to maintain employment.31,37 B1D is currently associated
with the highest suicide rate of all psychiatric illnesses with
one in four individuals suffering from B1D reporting a suicide attempt, which is the largest contributor to the premature mortality seen in the disease.38,39
PATHOPHYSIOLOGY OF BIPOLAR

1 DISORDER

Current evidence suggests B1D is a product of a constellation of immune-mediated inflammation in combination
with abnormalities in brain structure, circuitry, neurotransmitter signaling, and intrinsic activity.40–46 Levels of immune-regulated inflammatory markers, such as interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α),
interferon-γ (IFN-γ), and C-reactive protein (CRP) are elevated in patients with B1D, along with increased levels
of CD4+ T cells in circulation, suggesting an association
between a pro-inflammatory state and B1D.40,47–56 Manic
episodes specifically seem to coincide with state-dependent
inflammatory activation and increased levels of the afore-
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mentioned inflammatory markers as shown in a recent longitudinal study.40,57
Neuroimaging studies have shown gray matter abnormalities without consistency between patients with B1D;
however, imaging has consistently shown reduced white
matter volumes and alterations in white matter connections, especially in the cingulum, corpus callosum, frontal
brain regions, and tracts connecting regions of the limbic
system.40,58–63 It is postulated that the diffuse white matter damage may be potentiated by a CD4+ T cell-mediated
immune response causing cytotoxic effects.40 The white
matter effects are most consistently seen in the limbic system, which is involved in the modulation of homeostasis
and neurotransmitter signaling in response to stress.40,64,65
Additionally, increased amygdala volume and decreased
hippocampal volume are consistently seen in patients with
B1D.40,41 The combination of effects observed in the limbic
network localizes B1D pathophysiology to the limbic system as a result of the localized immune-mediated white
matter damage.40
Neurochemical changes observed in patients with B1D
include hyperactivity in the hypothalamus-pituitaryadrenal (HPA) axis, transient increases in dopamine and
norepinephrine signaling, and changes in serotonin metabolism.40,66,67 Much like the etiology of the white matter
changes seen in BD, data suggests the neurotransmitter
dysregulation is induced by the stress response and resultant immune-mediated inflammation.40
Abnormalities in functional connectivity have been observed in association with B1D in functional magnetic resonance imaging (MRI) studies, most often as functional disconnection the raphe nuclei involved in serotonin signaling
and increased thalamus-sensorimotor network connectivity.40,46,68,69
Together, the data show that the pathophysiology of B1D
is ultimately the result of immune dysregulation with a
pro-inflammatory state causing white matter damage in the
limbic system, leading to changes in neurotransmitter signaling and functional brain connectivity and activity, precipitating the presentation of the mania and depression
seen in B1D.40

CURRENT TREATMENT OF SCHIZOPHRENIA
AND BIPOLAR 1 DISORDER
CURRENT TREATMENT OF SCHIZOPHRENIA

Related to its disease complexity, there are several therapeutic options available to treat the various positive, negative, and cognitive symptoms of schizophrenia, including
first-generation antipsychotics (FGAs), atypical antipsychotics (AAPs), third-generation antipsychotics, as well as
other nonpharmacologic treatments such as cognitive-behavioral therapy (CBT) and exercise.70–74
The first pharmacologic treatments for schizophrenia
were initially developed in the 1960s based on the
dopamine hypothesis, which emphasized the role of excessive dopamine in the production of positive symptoms
of schizophrenia.71,74,75 The FGA chlorpromazine supports
this hypothesis and was the first FDA-approved pharmacologic therapy for schizophrenia.74,76 Chlorpromazine re-

duces positive symptoms by non-selectively antagonizing
dopamine-2 (D2) receptors, however, it has little effect on
negative and cognitive symptoms. Chlorpromazine’s lack of
selectivity to dopamine receptors in the mesolimbic pathway causes many side effects including parkinsonian-like
extrapyramidal effects because of D2 receptor antagonism
in the nigrostriatal pathway. The side effects of FGAs led to
the development of more selective treatment options such
as AAPs and third-generation antipsychotics, which each
target multiple receptor types.74,76
AAPs differ from FGAs by exhibiting greater antagonism
at serotonin (5-HT2A) receptors than at D2 receptors in the
nigrostriatal pathway and bind with higher affinity to D4
than D2 receptors, resulting in a lower occurrence of extrapyramidal side effects and reduction of negative symptoms.74 Clozapine is the only FDA-approved AAP for treatment-resistant schizophrenia, which is most commonly
diagnosed when patients fail to respond to at least two
other antipsychotics.73 Clozapine, however, is associated
with various autonomic side effects such as hypotension
and reflex tachycardia, as well as agranulocytosis, drooling,
constipation and seizures.71,74 Olanzapine and risperidone
are newer AAPs, with fewer autonomic side effects and neither are associated with agranulocytosis.71,74,77 Third generation antipsychotics such as aripiprazole, aripiprazole,
and cariprazine are newer treatments that exhibit partial
agonist of the D2 receptor.74,78
Other nonpharmacologic treatments of schizophrenia
such as CBT and exercise, are reported to reduce negative
and cognitive symptoms of schizophrenia, which can be
used in conjunction with pharmacologic therapy.72,79 Decreased hippocampal volume is associated with impairment
of executive functioning and cognition in schizophrenia.79
Pajonk et al79 found that three months of aerobic exercise
increased hippocampal volume which also correlated with
increased short-term memory test scores in patients with
schizophrenia. Recently, research investigating the use of
combination and multi-target drug therapies to treat schizophrenia has emerged.74 Targeting multiple neurotransmission pathways, with multiple receptors, could potentially allow for increased therapeutic efficacy and decreased
unwanted side effects.
CURRENT TREATMENT OF ACUTE MANIA IN BIPOLAR
DISORDER

1

Lithium carbonate and chlorpromazine were among the
first pharmacologic treatments for acute mania in B1D in
the 1940s and 1950s, however the acceptance of lithium was
delayed due to toxicity observed in patients given unregulated dosages.80 Subsequently, the utilization of AAPs was
also proven efficacious in the treatment of acute mania.81
AAPs such as aripiprazole, asenapine, cariprazine, olanzapine, paliperidone, risperidone, and ziprasidone, as well as
quetiapine (in higher doses), were authorized for treatment
of dysphoric and mixed state mania.82,83 Sodium divalproex
(valproate) and carbamazepine are two anticonvulsants approved for the treatment of acute mania, however, they have
not shown efficacy in long-term prophylaxis.81,82
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CURRENT TREATMENT OF DEPRESSION IN BIPOLAR
DISORDER

1

In patients with B1D, several studies reported that depressive episodes account for nearly three quarters of the mean
proportion of weeks ill (approximately 50%), causing depression to be a major contributor to the burden of illness
in B1D.82,84,85 Current treatments for acute depressive
episodes exhibit inconsistent results, and thorough investigation into long-term prophylaxis is limited. Despite a
lack of evidence showing efficacy and safety, B1D-depression is often treated with antidepressants. In this regard,
some clinicians utilize antidepressants only in acute treatment of B1D-depression related to concern of induction of
mood switching to hypomania, mania, and mixed states.86

OLZ/SAM MECHANISM OF ACTION

LONG-TERM PROPHYLAXIS

Lithium has been a component of the first-line treatment of
B1D for almost 60 years.87 Along with its more prominent
effects against mania and hypomania, lithium may also
have long-term benefits against B1D-depression recurrence
and suicide risk reduction in B1D patients.88 Lamotrigine is
an anticonvulsant that is FDA-approved for long-term B1D
prophylaxis and has reportedly limited the risk of recurrence of depressive episodes, however, it lacks efficacy in
managing acute mania.89
TREATMENT RESISTANCE BIPOLAR

preclinical studies. For example, a decrease in weight gain
was reported in μ-, κ-, and δ- opioid receptor knockout
mice, despite no differences in caloric intake in μ- and κopioid receptor knockouts.99 Therefore, antagonism of the
opioid system by samidorphan was introduced to minimize
olanzapine-induced weight gain and increase olanzapine’s
use as a treatment for schizophrenia and B1D.94 However,
although samidorphan decreases olanzapine-induced
weight gain, it has not been shown to decrease any of the
other metabolic adverse effects of olanzapine therapy, such
as dyslipidemia and type II diabetes, potentially indicating
a direct effect of olanzapine on metabolism.94 Contraindications for OLZ/SAM include patients taking opioids, and
patients going through acute opioid withdrawal.100

1 DISORDER

For B1D patients resistant to pharmacotherapy, nonpharmacologic therapies such as transcranial magnetic stimulation could be a promising new treatment option for reducing depressive symptoms and mania. However, current
studies have reported mixed results, therefore more confirmatory research is needed.90

OLZ/SAM DRUG INFO
OLZ/SAM, marketed as Lybalvi, became FDA-approved for
the treatment of adults with schizophrenia and B1D on June
1, 2021.91 OLZ/SAM is a daily oral tablet composed of multiple dose strengths of olanzapine, (5, 10, 15, 20 mg) depending on the disorder being treated, and a fixed dose of
10mg of samidorphan.92 Specifically, OLZ/SAM treatment
in B1D is used for acute management of manic/mixed
episodes, maintenance monotherapy, or as an adjunct to
lithium or valproate.91 Olanzapine is one of the most efficacious AAPs in the treatment of both schizophrenia and B1D
and is associated with fewer extrapyramidal effects than
with FGA treatment.93,94 However, compared to other
AAPs, olanzapine is associated with a greater chance of
metabolic abnormalities such as dyslipidemia, type II diabetes, and weight gain, limiting its clinical use and affecting
treatment compliance.93–97
In studies enrolling healthy adults and adults with schizophrenia, the combination of olanzapine with samidorphan, a μ-opioid receptor antagonist, mitigated weight gain
associated with olanzapine monotherapy.94,98,99 The opioid
system has been implicated in the role of mediating feeding
behavior, food reward, and metabolism in many clinical and

OLZ/SAM is a novel combination of olanzapine and samidorphan, that has been reported to mitigate the weight gain
seen in olanzapine monotherapy.91 Olanzapine has already
been proven to be efficacious in the treatment of schizophrenia and B1D through D2 receptor antagonism in the
mesolimbic system and 5-HT2A receptor antagonism in the
frontal cortex.96,101 Antagonism of D2 receptors decreases
positive symptoms of schizophrenia while antagonism of
5-HT2A receptors decreases negative symptoms.96,101 Several MRI studies also found increased activity in the prefrontal cortex during cognitive and emotional tasks in
schizophrenia patients treated by olanzapine, suggesting a
pattern of positive effects on cognition as well.102
The role of a said orphan in OLZ/SAM is to mitigate the
weight gain induced by olanzapine monotherapy.99 Samidorphan binds with high affinity to μ-, κ-, and δ-opioid
receptors and primarily functions as a μ-opioid antagonist
and partial agonist at κ- and δ-opioid receptors.98,103,104
Samidorphan has been reported to decrease activation of
the mesolimbic reward system when used in combination
with buprenorphine in the treatment of the major depressive disorder.105 While the mechanism of action for reducing weight gain via samidorphan is not entirely understood,
opioid receptors are present throughout the mesolimbic
system and their antagonism by the μ-opioid antagonist
naltrexone, is observed to reduce cravings for sweet/rich
foods.98,104 Results of a 12-week, phase-II trial, found that
OLZ/SAM treatment in schizophrenia patients, is associated with significantly less weight gain than olanzapine
monotherapy.106 Therefore, samidorphan inhibition of the
mesolimbic reward system by μ-opioid receptor antagonism
is presumed to be the source of the observed decrease in
olanzapine-induced weight gain in patients administered
OLZ/SAM.98,105

PHARMACOKINETICS AND
PHARMACODYNAMICS OF OLZ/SAM
A phase I study assessing the pharmacokinetic profile of
olanzapine and samidorphan in schizophrenia patients after once-daily 14-day administration of OLZ/SAM, found
that steady-state concentrations of both drugs were reached
linearly after one week.106 Olanzapine is primarily metab-

Health Psychology Research

5

Combination Olanzapine and Samidorphan for the Management of Schizophrenia and Bipolar 1 Disorder in Adults: A Narrative...

olized by cytochrome P450 (CYP) 1A2 mediated oxidation
and also via direct glucuronidation by uridine 5’-diphosphate-glucuronosyltransferase 1A4.107 Therefore, caution
should be exercised with coadministration of either CYP1A2
inhibitors, such as fluvoxamine, or CYP1A2 inducers including carbamazepine or rifampin. Samidorphan is mainly
metabolized by CYP3A4, consequently, caution should also
be taken when co-administering CYP3A4 inducers and inhibitors.107 Heavy smoking also induces CYP1A2 leading to
increased clearance of olanzapine by 30-55% when compared to nonsmokers.108
Physiologically based and clinically developed pharmacokinetic models using healthy individuals and patients
with schizophrenia, concluded that samidorphan did not
alter the pharmacokinetics of olanzapine when co-administered across the clinical dose range (5-30mg), which is
consistent with previously published studies.106,107,109 A
study assessing hepatic and renal impairment effects on
the pharmacokinetics of olanzapine and samidorphan, reported that patients with moderate hepatic impairment experienced higher absorption and systemic exposure to olanzapine than healthy participants, and those with renal
impairment had a 33% and 56% decrease in total body
clearance of olanzapine and samidorphan, respectively.110
Olanzapine binds with high affinity at dopamine D1-4,
5HT2a/2c, 5HT6, histamine-1 (H1), and adrenergic-1 (α1)
receptors.100 Blocking dopamine receptors, increases the
risk of side effects such as akathisia, extrapyramidal symptoms, tardive dyskinesia, and neuroleptic malignant syndrome.101 Samidorphan binds with high affinity to μ-, κ-,
and δ-opioid receptors, primarily functioning as a μ-opioid
antagonist and κ- and δ-opioid partial agonists.98,103,104 In
a phase II study, significantly lower weight gain of about
37% was observed in patients taking OLZ/SAM compared to
those treated with olanzapine monotherapy.104

CLINICAL STUDIES: SAFETY AND EFFICACY
OLZ/SAM has shown statistical and clinical efficacy and
safety in several studies.111 In the OLZ/SAM development
program, 18 studies were used to evaluate the safety and
the antipsychotic and weight-mitigating efficacy. The studies concluded the efficacy and safety of OLZ/SAM were similar to olanzapine, with reduced weight gain overall.111
In a recent study from 2015-2017, 401 adults with clinically diagnosed schizophrenia who were experiencing an
acute episode of psychosis were administered ≥1 dose of
OLZ/SAM. Of the 401 patients, 352 patients completed the
treatment. Results showed significant improvement in the
Positive and Negative Syndrome Score (PANSS) and Clinical
Global Impression-Severity (CGI-S) score within 4 weeks
of patients receiving OLZ/SAM versus placebo. Although
OLZ/SAM showed the most efficacy, it also had the highest
percentage of adverse effects (54.5% vs. 44.8% in placebo)
of weight gain, somnolence, dry mouth, anxiety, and
headache. Overall, OLZ/SAM was well tolerated and had efficacy and safety similar to that of olanzapine.112
In an open-label extension study, the long-term tolerability, safety, and efficacy were evaluated in patients with
schizophrenia. Semi-structured one hour-long interviews
were conducted in which all 41 patients indicated their di-

agnosis of schizophrenia had impacted personal, social, and
financial aspects of their lives. Of the 41 patients that were
administered OLZ/SAM, 39 patients had reported improvements in both positive and negative symptoms of psychosis.
Overall, most of the patients were satisfied with their treatment.113
In a 52-week open-label extension study, OLZ/SAM was
concluded to improve schizophrenia symptoms, while mitigating weight-gain in patients. Of the 281 patients that enrolled, 183 patients completed the 52-week trial. PANSS total and CGI-S scores declined in all patients that completed
the trial. Increases in weight gain were stabilized by week
6, with an average 2.79% increase in weight gain. Overall,
OLZ/SAM was well tolerated.114
In a randomized, double-blind, placebo-controlled study
of 106 healthy, male normal weight volunteers, OLZ/SAM
was shown to have similar safety and tolerability as olanzapine. However, OLZ/SAM had less side effects such as
nausea, weight gain and metabolic risk. Further studies are
needed to explore the side effects and efficacy of additional
doses over a longer duration of time in schizophrenic patients.98
In randomized, controlled trials, OLZ/SAM and olanzapine-monotherapy were compared in healthy volunteers to
determine short-term weight and cardiometabolic changes
in these patients. In the OLZ/SAM group, weight changes
were not statistically different than the olanzapine groups.
However, OLZ/SAM was found to help prevent olanzapineinduced weight gain in healthy males with a lower initial
BMI. This study concludes there is not sufficient evidence
that OLZ/SAM prevents olanzapine-induced weight gain
and olanzapine-induced cardiometabolic abnormalities.115
In a 24-week phase 3 double-blind trial, OLZ/SAM was
assigned to 280 patients while olanzapine-monotherapy
was assigned to 281 patients. Of these patients, 538 had
post-baseline weight assessments. Of these 538 patients,
the least-squares mean percent weight change from baseline of OLZ/SAM patients was approximately 4.21%; the
olanzapine-monotherapy group was 6.59%. In addition,
schizophrenia symptom improvement was similar to the
olanzapine-monotherapy treatment. This study concluded
that OLZ/SAM treatment was associated with similar schizophrenia symptom improvement, but with significantly less
weight gain and smaller increases in waist circumference.116
In a multicenter, randomized phase 2 study of OLZ/SAM,
the efficacy and weight gain side effects of OLZ/SAM were
observed. Seventy-five patients received olanzapine plus
placebo, and the rest received OLZ/SAM in different
dosages (N=80; 5 mg, N=86; 10 mg, N=68; 20 mg). Results
showed that OLZ/SAM resulted in statistically significant
lower weight gain compared to olanzapine plus placebo patients, with OLZ/SAM showing a 37% lower weight gain
compared to olanzapine plus placebo. In addition, the
safety and efficacy of OLZ/SAM had a similar profile to olanzapine plus placebo, making OLZ/SAM a better option for
mitigating weight gain while simultaneously treating schizophrenia.99
In phase 3, a 52-week open-label extension study of OLZ/
SAM in patients with schizophrenia, the safety, efficacy, tolerability, and side effects were studied. Patients were di-
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vided randomly into a 24-week, double-blind phase 3 study
to compare weight gain in patients administered OLZ/SAM
versus olanzapine-monotherapy. Two hundred sixty-five
patients were administered OLZ/SAM, with 167 completing
the extension of the remaining study. Fasting lipid,
glycemic parameters, and PANSS scores remained stable
throughout the study in patients receiving OLZ/SAM. CGI-S
scores remained 3 or less in 81.3% of the patients, indicating mild illness severity. Results indicated patients that who
were administered OLZ/SAM tolerated the medication well
with significant results including smaller waist circumferences, smaller weight gain, and efficacy of the medication
combination.117,118
In an open-label, randomized study, 48 healthy, nonsmoking participants were randomly assigned to either
generic olanzapine-monotherapy, OLZ/SAM, or Zyprexa,
brand olanzapine (B-OLZ), in a 1:1:1:1:1:1 randomization.
The pharmacokinetics of the drug-drug interactions between olanzapine and samidorphan were studied. Results
indicated that OLZ/SAM was not shown to have any safety
concerns nor affect the pharmacokinetics and bioavailability of olanzapine. In general, OLZ/SAM was well-tolerated
by patients.119
Because OLZ/SAM is used in both schizophrenia and
B1D, medications such as lithium or valproate are commonly prescribed along with OLZ/SAM. In an open-label,
single-sequence two-cohort study, 34 healthy adults were
administered lithium carbonate or divalproex sodium, once
every 12 hours on days 1-7. On days 8-18, participants were
administered olanzapine. The safety profiles of lithium and
valproate while administered with OLZ/SAM were similar
to the safety profile of what was previously reported for
lithium and valproate. Administration of OLZ/SAM did not
have a clinically significant effect on the pharmacokinetics
of lithium or valproate and was generally well-tolerated.120
Because OLZ/SAM has an antipsychotic component, QTc
intervals should be monitored for patients on this drug. In
a randomized double-blind, placebo-controlled study, 100
patients with stable schizophrenia were randomized to receive OLZ/SAM or a placebo. Electrocardiograms (ECGs)
and plasma drug concentrations were observed before and

after dose administration. No clinically significant QTc effects were observed between OLZ/SAM doses.121
Although several studies have indicated OLZ/SAM has
similar improvement rates to olanzapine-monotherapy, it
has not had the same results in patients with a comorbidity
of alcohol use disorder (AUD). In phase 2 double-blind
study, patients with schizophrenia and AUD were enrolled
in a 1:1 randomized trial of OLZ/SAM and placebo. After
30-60 weeks of treatment, no significant difference was observed between schizophrenics with comorbidity of AUD
treated with OLZ/SAM vs olanzapine-monotherapy.122

CONCLUSION
Schizophrenia and B1D are severe psychiatric illnesses with
a significant economic burden of disease, high comorbidity
rates, and poor prognoses despite relatively low prevalence
rates.3–5,9,10,32 Current pharmacological treatments of
schizophrenia include FGAs, AAPs, and third-generation
antipsychotics.70–74 The current pharmacological treatment of B1D includes AAPs and lithium.81,87 The use of
combination drugs to treat psychiatric conditions is an
emerging field with the primary goal of increasing therapeutic efficacy and decreasing undesirable side effects
through targeting neurotransmission pathways.74
OLZ/SAM is approved by the FDA to treat schizophrenia
and B1D. Olanzapine has proven effective for the treatment
of schizophrenia and B1D through dopamine and serotonin
receptor antagonism.96,101 Samidorphan mitigates the
weight gain side effects of olanzapine by antagonizing μ-,
κ-, and δ-opioid receptors.98,103,104 In clinical trials, OLZ/
SAM showed similar efficacy in treating schizophrenia and
B1D and exhibited less side effects (weight gain, somnolence, dry mouth, anxiety, headache) when compared to
olanzapine-monotherapy.112 No concerns regarding safety,
pharmacokinetics, or bioavailability were identified during
clinical trials.119 Most patients reported improvements in
symptoms of psychosis, reduced weight gain, and overall
satisfaction with the combination treatment. OLZ/SAM has
shown to be an effective and safe pharmaceutical option for
the clinical management of schizophrenia and B1D.113,116
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Table 1. Lybalvi Studies and Findings
Author and
Year

Groups Studied and Intervention

Results and Findings

Potkin et
al112 (2020)

401 adults with clinically diagnosed schizophrenia who were
experiencing an acute episode of psychosis were
administered >1 dose of OLZ/SAM

Results indicated a significant improvement in PANSS
and CGI-S total scores within 4 weeks in patients
receiving OLZ/SAM versus placebo.

OLZ/SAM was well tolerated and had efficacy and
safety similar to that of olanzapine-monotherapy

Simmons et
al113 (2021)

41 patients with schizophrenia whose diagnosis of
schizophrenia had impacted personal, social, and financial
aspects of their lives were administered OLZ/SAM

Results indicated improvements in both positive and
negative symptoms of psychosis in 39 of these patients

Most of the patients were satisfied with their
treatment of OLZ/SAM

Citrome et
al111 (2021)

18 studies were used to evaluate the antipsychotic and
weight-mitigating efficacy and safety of OLZ/SAM in >1600
patients

Results indicated that the efficacy and safety of OLZ/
SAM were similar to olanzapine, with reduced weightgain overall

The efficacy and safety of OLZ/SAM were similar to
olanzapine-monotherapy, with reduced weight-gain
overall

Yagoda et
al114 (2021)

Patients with clinically diagnosed schizophrenia who
completed the first phase of the ENLIGHTEN-1 study
program were administered OLZ/SAM (N=277
administered >1 dose OLZ/SAM; N=183 completed 52
weeks of program)

Results indicated PANSS total and CGI-S scores
declined in all patients that completed the trial.
Increases in weight gain were stabilized by week 6,
with an average 2.79% increase in weight gain

OLZ/SAM was concluded to improve schizophrenia
symptoms, while mitigating weight-gain in patients

Brunette et
al122 (2020)

234 patients with schizophrenia and AUD were enrolled in a
1:1 randomized trial of OLZ/SAM and placebo

Results indicated that no significant difference was
observed between schizophrenics with comorbidity of
AUD treated with OLZ/SAM vs olanzapine

OLZ/SAM can be used in schizophrenics with
comorbidity of AUD. However, it is not superior to
olanzapine and further studies are needed

Silverman et
al98 (2018)

106 healthy, male normal weight volunteers were
administered either OLZ/SAM, SAM, or placebo in a 2:2:1:1
ratio

Results indicated that OLZ/SAM was shown to have
similar safety and tolerability as metabolic risk

Although OLZ/SAM had lesser side effects than
olanzapine, further studies are needed in order to
explore the side effects and efficacy of additional
doses over a longer duration of time in schizophrenic
patients

Sun et al121
(2020)

100 patients aged 18 to 60 years with stable schizophrenia
were administered either OLZ/SAM or OLZ/SAM-matched
placebo in a 3:2 ratio

Results indicated there were no clinically significant
QTc effects, including QT prolongation, across the
OLZ/SAM doses, ranging from 110 to 160 ng/mL

OLZ/SAM has no significant effect on QT intervals

Sun et al120
(2020)

34 healthy adults were administered lithium carbonate or
divalproex sodium in a 1:1 ratio. On days 8-18, participants
were administered olanzapine.

Results indicated that the safety profiles of lithium and
valproate while administered with OLZ/SAM was
similar to the safety profile of what was previously
reported for lithium and valproate.

Administration of OLZ/SAM did not have a clinically
significant effect on the pharmacokinetics of lithium or
valproate and was generally well-tolerated.

Sun et al119
(2018)

48 healthy, nonsmoking participants were randomly
assigned to either olanzapine monotherapy, OLZ/SAM, or BOLZ in a 1:1:1:1:1:1 randomization where pharmacokinetics
of the drug-drug interactions between olanzapine and
samidorphan were studied.

Results indicated that OLZ/SAM was shown to not
have any safety concerns nor affect the
pharmacokinetics and bioavailability of olanzapine
monotherapy

Simultaneous administration of olanzapine and
samidorphan does not affect the bioavailability of
olanzapine. In general, OLZ/SAM is well-tolerated by
patients

Srisurapanont
et al115
(2021)

OLZ/SAM and olanzapine administration were compared in
1195 volunteers

Results indicated that the OLZ/SAM group’s weight
changes were not statistically different than the
olanzapine group

There is not sufficient evidence that samidorphan
prevents olanzapine-induced weight gain and
olanzapine-induced cardiometabolic abnormalities.
Samidorphan was well-tolerated by the patients
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treated with olanzapine in this study.
Correll et
al116 (2020)

OLZ/SAM was administred to 280 patients while olanzapine
was assigned to 281 patients to compare the effects of OLZ/
SAM on weight gain

Results indicated that schizophrenia symptom
improvement was similar to the olanzapine treatment
with statistically significant weight differences

This study concluded that OLZ/SAM treatment was
associated with similar schizophrenia symptom
improvement, but with significantly less weight gain
and smaller increases in waist circumference

Martin et al99
(2019)

75 patients received olanzapine plus placebo, and the rest
received OLZ/SAM in different dosages (N=80; 5 mg, N=86;
10 mg, N=68; 20 mg) to test OLZ/SAM weight gain
mitigation

Results indicated that OLZ/SAM resulted in
statistically significant lower weight gain compared to
olanzapine plus placebo patients, with OLZ/SAM
showing a 37% lower weight gain compared to
olanzapine plus placebo.

Safety and efficacy of OLZ/SAM had a similar profile to
olanzapine plus placebo, making OLZ/SAM a better
option for mitigating weight gain while simultaneously
treating schizophrenia

Kahn et al117
(2021)

265 patients with schizophrenia were administered either
OLZ/SAM or olanzapine to compare the efficacy, safety,
tolerability, and side effects of OLZ/SAM to olanzapine

Results indicated that fasting lipid, glycemic
parameters, and PANSS scores remained stable
throughout the study in patients receiving OLZ/SAM.
CGI-S scores remained 3 or less in 81.3% of the
patients, indicating mild illness severity.

Patients that were administered OLZ/SAM tolerated
the medication well with significant results including
smaller waist circumferences, smaller weight gain and
efficacy of the medication combination

Kahn et al118
(2021)

167 patients with schizophrenia were administered either
OLZ/SAM or olanzapine to compare the efficacy, safety,
tolerability and side effects of OLZ/SAM to olanzapine

Results indicated that fasting lipid, glycemic
parameters and PANSS scores remained stable
throughout the study in patients receiving OLZ/SAM.
CGI-S scores remained 3 or less in 81.3% of the
patients, indicating mild illness severity.

Patients that were administered OLZ/SAM tolerated
the medication well with significant results including
smaller waist circumferences, smaller weight gain and
efficacy of the medication combination

Combination olanzapine and samidorphan (OLZ/SAM); Positive and Negative Syndrome Score (PANSS); Clinical Global Impression-Severity (CGI-S); alcohol use disorder (AUD); brand- olanzapine (B-OLZ)
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